Table 2.
Baseline clinical characteristics
| Case | Sex | Age | Heart failure cause disease | BMI (kg/m 2 ) | eGFR (mL/min/1.73 m 2 ) | LVEF (%) | SPO2 (%) | Medications | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β-blocker | ACEI/ARB | MRA | Loop diuretic | Tolvaptan | Inotropic agent | Anti coagulants | ||||||||
| 1 | F | 75 | DCM, AF | 16.7 | 12 | 15 | 96 | + | + | + | + | + | Warfarin | |
| 2 | M | 67 | DCM, AF | 21.6 | 26 | 26 | 96 | + | + | + | + | + | Rivaroxaban | |
| 3 | F | 84 | IHD, AS | 18.4 | 16 | 74 | 99 | + | + | |||||
| 4 | M | 95 | IHD | 24.4 | 13 | 61 | 97 | + | + | + | ||||
| 5 | F | 81 | AF, MR | 24.5 | 17 | 23 | 99 | + | + | + | + | + | Warfarin | |
| 6 | M | 77 | ICM | 17.9 | 41 | 22 | 97 | + | + | + | + | |||
| 7 | M | 74 | DCM, AF | 21.4 | 29 | 38 | 96 | + | + | + | + | Warfarin | ||
| 8 | F | 88 | ICM | 24.8 | 14 | 33 | 93 | + | + | |||||
DCM Dilated cardiomyopathy, ICM Idiopathic cardiomyopathy, IHD Ischemic heart disease, AF Atrial fibrillation, AS Aortic stenosis, MR Mitral regurgitation, LVEF Left ventricular ejection fraction, ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, MRA Mineralocorticoid receptor antagonist